ABL1 and breast cancer: A review showed p190 was found similar to p210 in Ph+ AML, and proposed that the p190 transcript was in favor of the diagnosis of Ph+ AML.[9] It was worth noting that ABL1 mutations were more common in CML-BC, with a frequency as high as 80%.[13–15] The ABL1 mutations have not been reported in Ph+ AML patients.[3] The examinations of our patient showed the existence of p190, whereas the absence of ABL1 kinase domain mutations suggesting that ABL1 mutations may be an important biomarker for the identification of both Ph+ AML and CML-BC.